Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (1358)	1/7/2013 11:13:33 AM
From: The Ox	1 Recommendation Read Replies (3) \| Respond to of 8239

AMZN hitting new highs

To: The Ox who wrote (1358)	1/14/2013 2:13:47 PM
From: The Ox	Respond to of 8239

Did a quick review of the contest list and it's up 15% since the start of the year.... No way will that keep up! 9 out of ten are up and CYTK is up 66%! Great start....but let's see how I finish. Haven't done well at all over the course of the year with my previous contestants!! Maybe this year IS next year....?!?

To: The Ox who wrote (1358)	1/31/2013 1:47:41 PM
From: The Ox	Respond to of 8239

CLSN's phase III trial failed. Stock down 80% today....

To: The Ox who wrote (1358)	2/25/2013 8:35:07 AM
From: The Ox	Read Replies (2) \| Respond to of 8239

Dynavax Technologies Corporation (NASDAQ: DVAX) announced Monday that it received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine. In the CRL, the FDA specified that the indication in adults 18-70 years of age cannot be approved without further evaluation of safety in this broad age group. The FDA also continues to express concern that novel adjuvants may cause rare autoimmune events. However, the Agency indicated its willingness to continue discussions regarding a more restricted use of HEPLISAV. Dynavax plans to discuss the CRL with the FDA to identify the most expeditious path to approval for HEPLISAV, particularly in adults who may receive the greatest benefit from HEPLISAV. Furthermore, the FDA requested additional data from Dynavax's process validation program and clarifying information on the manufacturing controls and facilities related to the assurance of the quality of the commercial product. Dynavax believes it can provide the information but the exact timeframe for its response cannot be determined until it has met with the Agency. Dynavax plans to meet with the FDA to discuss the steps necessary for potential approval of HEPLISAV and currently believes the meeting can take place within 6 weeks. Following its meeting with the FDA, Dynavax will provide updates as appropriate.

To: The Ox who wrote (1358)	3/7/2013 9:17:38 AM
From: The Ox	Read Replies (2) \| Respond to of 8239

ACHN, EXEL and ZIOP all looking solid the last few days. Some of the others look pretty poorly, to say the least!

To: The Ox who wrote (1358)

3/21/2013 11:41:32 AM

From: The Ox

Read Replies (4) | Respond to of 8239

PCYC is in my charity portfolio. Yesterday, I was amazed at the target price put on the stock by Wedbush, $160!!

Keep in mind 2 years ago the stock was trading at $5/share. They have a lot going for them and here is a note written by 247Wallst:
247wallst.com

Stock has backed off $10 from it's recent high, fwiw.

To: The Ox who wrote (1358)	4/10/2013 1:34:18 PM
From: The Ox	Read Replies (1) \| Respond to of 8239

ONTY trying to break into the gap....